QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$8.18
+0.23 (+2.89%)
(As of 01/31/2023 11:12 AM ET)
Add
Compare
Today's Range
$7.99
$8.19
50-Day Range
$5.62
$8.16
52-Week Range
$5.42
$18.73
Volume
646,820 shs
Average Volume
5.05 million shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
144.7% Upside
$19.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.47mentions of Iovance Biotherapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Acquiring Shares
$65.19 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.48) to ($2.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

151st out of 1,055 stocks

Biological Products, Except Diagnostic Industry

26th out of 170 stocks


IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
Iovance Biotherapeutics Recent Insider Activity
Iovance Declines Following FDA Feedback On Its Melanoma Drug Lifileucel
Robert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)
Recap: Iovance Biotherapeutics Q3 Earnings
IOVA Iovance Biotherapeutics, Inc.
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.50
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+138.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$-342,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
145,845,000
Market Cap
$1.29 billion
Optionable
Optionable
Beta
0.38

Social Links


Key Executives

  • Frederick G. Vogt
    President, CEO, Secretary & General Counsel
  • Igor P. Bilinsky
    Chief Operating Officer
  • Jean-Marc Bellemin
    CFO & Principal Accounting Officer
  • Friedrich Graf Finckenstein
    Chief Medical Officer
  • Kristin Lanzi
    Vice President-Information Technology













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 1-year target prices for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA stock has increased by 24.4% and is now trading at $7.95.
View the best growth stocks for 2023 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.64%), Rice Hall James & Associates LLC (1.15%), ARK Investment Management LLC (0.52%), New York State Common Retirement Fund (0.37%), Peregrine Capital Management LLC (0.19%) and Hennion & Walsh Asset Management Inc. (0.11%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $7.95.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.25 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 1/31/2023 by MarketBeat.com Staff